HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| (28 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
Welcome! | Ian Welcome! | ||
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' | '''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.''' | ||
| Line 89: | Line 89: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| | |[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||Daynna Wolff | ||
| || || || ||FQR|| || | |10/14/25|| || || ||FQR|| || | ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified | |Chronic Eosinophilic Leukemia, Not Otherwise Specified | ||
|Chelsea D. Kramish; Daynna J.Wolff | |Chelsea D. Kramish; Daynna J.Wolff | ||
| Line 281: | Line 281: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| | |[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| | ||
| || || || ||FQR|| || | | || || || ||FQR|| || | ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | |Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable | ||
| Line 1,031: | Line 1,031: | ||
| | | | ||
|Check reference format | |Check reference format | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | | | ||
| Line 1,094: | Line 1,110: | ||
| | | | ||
|Previously within myeloid section under JH/MS editors | |Previously within myeloid section under JH/MS editors | ||
|- | |- | ||
|[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | |[[HAEM5:Langerhans cell histiocytosis|Langerhans cell histiocytosis]] | ||
| Line 1,385: | Line 1,385: | ||
|Date completed by author: 01/24/2022 | |Date completed by author: 01/24/2022 | ||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]] | |||
|Disease | |Disease | ||
| | |To be covered in B-ALL, NOS | ||
| | | | ||
| | | | ||
| Line 1,403: | Line 1,419: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera | |Miguel Gonzalez Mancera, MD | ||
| | | | ||
| | | | ||
|Complete (pending review by SK) | |||
| | | | ||
|SK | |SK | ||
| Line 1,419: | Line 1,435: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera | |Miguel Gonzalez Mancera, MD | ||
| | | | ||
| | | | ||
|Complete (pending review by SK) | |||
| | | | ||
|SK | |SK | ||
| Line 1,435: | Line 1,451: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]] | ||
|Disease | |Disease | ||
|Holli Drendel | |Holli Drendel, PhD | ||
|Nov 11/2025 | |||
| | | | ||
| | |Pending | ||
| | | | ||
|SK | |SK | ||
| Line 1,449: | Line 1,465: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |||
|Disease | |||
|Karin Miller, MD | |||
|10/9/2025 | |||
|12/5/2025 | |||
| | |||
| | |||
|SK | |||
| | |||
| | |||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]] | |||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|SK | |||
| | |||
| | |||
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | |B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | ||
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | |Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG | ||
| Line 1,483: | Line 1,483: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]] | ||
|Disease | |Disease | ||
|Mark Evans, MD ( | |Mark G. Evans, MD | ||
| | |10/1/2025 | ||
| | |11/17/2025 | ||
|Complete (pending review by SK) | |||
|11/8/2025 | |||
|SK | |||
|Pending | |Pending | ||
| | | | ||
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | |B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | ||
| Line 1,499: | Line 1,499: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]] | ||
|Disease | |Disease | ||
| | |Gokce A. Toruner, MD, PhD | ||
| | |10/9/2025 | ||
| | |11/5/2025 | ||
| | |Pending | ||
| | | | ||
|SK | |SK | ||
| Line 1,515: | Line 1,515: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]] | ||
|Disease | |Disease | ||
| | |Gokce A. Toruner, MD, PhD | ||
| | |10/8/2025 | ||
| | |12/1/2025 | ||
| | |Pending | ||
| | | | ||
|SK | |SK | ||
| Line 1,531: | Line 1,531: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]] | ||
|Disease | |Disease | ||
|Lei Zhang | |Lei Zhang, PhD | ||
Michelle Fan (trainee) | Michelle Fan (trainee) | ||
| | |10/10/2025 | ||
| | |12/22/2025 | ||
|Pending | |Pending | ||
| | | | ||
| Line 1,548: | Line 1,548: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera | |Miguel Gonzalez Mancera, MD | ||
|10/1/2025 | |||
| | | | ||
|Pending | |||
| | | | ||
|SK | |||
|SK | |||
| | | | ||
| | | | ||
| Line 1,564: | Line 1,564: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]] | ||
|Disease | |Disease | ||
|Miguel Gonzalez Mancera | |Miguel Gonzalez Mancera, MD | ||
| | |10/1/2025 | ||
| | | | ||
|Pending | |||
| | | | ||
|SK | |SK | ||
| Line 1,580: | Line 1,580: | ||
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]] | |[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]] | ||
|Disease | |Disease | ||
|Aiko Otsubo | |Aiko Otsubo, PhD | ||
| | |10/10/2025 | ||
| | |11/24/2025 | ||
|Complete (pending SK review) | |||
|11/11/2025 | |||
|SK | |||
|Pending | |Pending | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 1,596: | Line 1,596: | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]] | ||
|Disease | |Disease | ||
|Lei Zhang | |Lei Zhang, PhD | ||
|10/10/2025 | |||
| | |12/22/2025 | ||
| | |||
|Pending | |Pending | ||
| | | | ||
| Line 1,612: | Line 1,611: | ||
|- | |- | ||
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | |[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]] | ||
|Disease | |Disease | ||
|Karin Miller, MD | |||
|10/9/2025 | |||
|11/24/2025 | |||
|Pending | |||
| | |||
|SK | |||
| | | | ||
| | | | ||
| Line 1,618: | Line 1,623: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|- | |- | ||
!Disease (5th Edition) | !Disease (5th Edition) | ||
| Line 1,644: | Line 1,643: | ||
|- | |- | ||
|RESOLVE 4th edition ALL-Related NON-WHO entities content | |RESOLVE 4th edition ALL-Related NON-WHO entities content | ||
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | |B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | ||
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 | |||
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements | |||
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions | |||
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) | |||
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | |||
|ISSUE- FIX | |ISSUE- FIX | ||
| Line 1,662: | Line 1,676: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | !Disease (5th Edition) | ||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty | |||
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG) | | ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG) | ||
| || | | || | ||
| Line 2,346: | Line 2,376: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo; | |[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo; | ||
| Line 2,402: | Line 2,416: | ||
|Prior Notes (4th Edition) | |Prior Notes (4th Edition) | ||
|- | |- | ||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
| | | colspan="15" | | ||
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)==== | |||
| | |- | ||
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK) | |||
| | | || | ||
-- | |NEW (No Prior) | ||
|- | |||
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK) | |||
| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,444: | Line 2,446: | ||
Karin Miller, MD | Karin Miller, MD | ||
|3/25/2024 | |3/25/2024 | ||
| || | | ||Pending | ||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,470: | Line 2,473: | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
|SK | |SK | ||
| Line 2,483: | Line 2,486: | ||
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | |[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]] | ||
|Disease | |Disease | ||
|Parastou Tizro, MD | |Parastou Tizro, MD; | ||
Celeste Eno, PhD | Celeste Eno, PhD; Sumire Kitahara, MD | ||
| | |9/23/2025 | ||
| | |11/4/2025 | ||
|Complete | |'''Complete''' | ||
| | |11/4/2025 | ||
|SK | |SK | ||
| | |11/6/2025 | ||
| | | | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,498: | Line 2,501: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); | |||
Michelle Don, MD, MS | |||
|9/24/2025 | |||
|12/9/2025 | |||
|Pending | |||
| ||SK|| || | |||
|T-cell Large Granular Lymphocytic Leukemia | |||
|Michelle Don, MD, MS | |||
|Pending | |||
| | |||
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee); | |||
Michelle Don, MD, MS | |||
| | |||
| | |||
|Pending | |||
| ||SK|| || | |||
|T-cell Large Granular Lymphocytic Leukemia | |||
|Michelle Don, MD, MS | |||
|Pending | |||
| | |||
| | | | ||
|- | |- | ||
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee); | |[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee); | ||
Michelle Don, MD, MS | Michelle Don, MD, MS | ||
| | |9/24/2025 | ||
| | |12/9/2025 | ||
| | |'''Complete''' | ||
| ||SK|| || | | 12/17/2025||SK|| 1/6/2026|| | ||
|Chronic Lymphoproliferative Disorder of NK Cells | |Chronic Lymphoproliferative Disorder of NK Cells | ||
|Michelle Don, MD | |Michelle Don, MD | ||
| Line 2,551: | Line 2,538: | ||
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD | |[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD | ||
|3/22/2024 | |3/22/2024 | ||
| | |follow-up needed | ||
| || ||SK|| || | |||
|Sézary Syndrome | |Sézary Syndrome | ||
|Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | |Madison E. Hannay, DO, Medical University of South Carolina Tingting Barrett, MD, Medical University of South Carolina Daynna J. Wolff, PhD, Medical University of South Carolina | ||
| Line 2,558: | Line 2,546: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease|| | |[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD | ||
Shashirekha Shetty, PhD | |10/15/2025||1/19/2026 | ||
| | |||
|Pending | |Pending | ||
| ||SK|| || | | ||SK|| || | ||
| Line 2,569: | Line 2,556: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease|| | !Disease (5th Edition) | ||
| | !Page Type | ||
| || | !<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | ||
| ||SK|| || | !Date Assigned to Author (5th Edition) | ||
|NEW (No Prior) | !Target Completion Date (5th Edition) | ||
|NEW (No Prior) | !Content Status (5th Edition)(Pending or Complete) | ||
|NEW (No Prior) | !Date Completed by Author (5th Edition) | ||
|NEW (No Prior) | !Associate Editor | ||
|NEW (No Prior) | !Date of Last Editor Review (5th Edition) | ||
|- | !Notes (5th Edition) | ||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Ian King, PhD | |||
|1/6/2026 | |||
| 2/3/2026|| | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee); | |[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee); | ||
Andrew Siref, MD | Andrew Siref, MD | ||
| | |10/14/2025 | ||
| | | |11/24/2025 | ||
| ||SK|| || | |'''Complete''' | ||
| 12/29/2025||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,593: | Line 2,597: | ||
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD | |[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD | ||
|3/22/2024 | |3/22/2024 | ||
| || || ||SK|| || | |follow-up needed|| || ||SK|| || | ||
|Mycosis Fungoides | |Mycosis Fungoides | ||
|Jane Scribner, MD and Daynna J. Wolff, PhD | |Jane Scribner, MD and Daynna J. Wolff, PhD | ||
| Line 2,603: | Line 2,607: | ||
Shashirekha Shetty, PhD | Shashirekha Shetty, PhD | ||
|7/1/2024 | |7/1/2024 | ||
| | |follow-up needed | ||
| | | | ||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,614: | Line 2,618: | ||
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); | |[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow); | ||
Shashirekha Shetty, PhD | Shashirekha Shetty, PhD | ||
|7/1/2024|| | |7/1/2024||follow-up needed | ||
| | | | ||
| ||SK|| || | | ||SK|| || | ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma | |Primary Cutaneous Anaplastic Large Cell Lymphoma | ||
| Line 2,623: | Line 2,627: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD | |||
Katelyn Swanson, DO (trainee) | |||
|11/19/2025 | |||
|12/19/2025 | |||
|'''Complete''' | |||
| 1/6/2026||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); | |||
Sumire Kitahara, MD | |||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease|| | |||
| | |||
| | | |||
| ||SK|| || | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|NEW (No Prior) | |||
|- | |||
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); | |||
Sumire Kitahara, MD | |||
|6/30/2024 | |6/30/2024 | ||
| | |11/9/2025 | ||
|Pending | |||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,663: | Line 2,654: | ||
Andrew Siref, MD | Andrew Siref, MD | ||
| | |10/14/2025||11/24/2025 | ||
| ||SK|| || | |'''Complete''' | ||
| 12/29/2025||SK|| 1/6/2026|| | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,678: | Line 2,670: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| | !Disease (5th Edition) | ||
| || || || ||SK|| || | !Page Type | ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | !<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | ||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | !Date Assigned to Author (5th Edition) | ||
|Pending | !Target Completion Date (5th Edition) | ||
| | !Content Status (5th Edition)(Pending or Complete) | ||
| | !Date Completed by Author (5th Edition) | ||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease|| | |||
| || || || ||SK|| || | |||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract | |||
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD | |||
|Pending | |||
| | |||
| | |||
|- | |- | ||
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| || | |[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| || | ||
| Line 2,695: | Line 2,703: | ||
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | |[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | ||
Andrew Siref, MD | Andrew Siref, MD | ||
| | |10/14/2025 | ||
| ||Pending|| ||SK|| || | | ||Pending|| ||SK|| || | ||
|Enteropathy-Associated T-cell Lymphoma | |Enteropathy-Associated T-cell Lymphoma | ||
| Line 2,705: | Line 2,713: | ||
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | |[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | ||
Andrew Siref, MD | Andrew Siref, MD | ||
| | |10/14/2025 | ||
| ||Pending|| ||SK|| || | | ||Pending|| ||SK|| || | ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | |Monomorphic Epitheliotropic Intestinal T-cell Lymphoma | ||
| Line 2,716: | Line 2,724: | ||
| || || || ||SK|| || | | || || || ||SK|| || | ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | |Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS) | ||
|Derick Okwan MD, PhD (Stanford | |Derick Okwan MD, PhD (Stanford) Sumire Kitahara MD (Cedars-Sinai) | ||
|Complete | |Complete | ||
|9/26/2022 | |9/26/2022 | ||
| Line 2,723: | Line 2,731: | ||
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee); | |[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee); | ||
Michelle Don, MD, MS | Michelle Don, MD, MS | ||
| | |9/24/2025 | ||
| | |11/9/2025 | ||
|Complete | |'''Complete''' | ||
| | |12/17/2025 | ||
|SK||1/6/2026|| | |||
|Hepatosplenic T-cell Lymphoma | |Hepatosplenic T-cell Lymphoma | ||
|Michelle Don, MD, MS | |Michelle Don, MD, MS | ||
| Line 2,732: | Line 2,741: | ||
|1/21/2021 | |1/21/2021 | ||
| | | | ||
|- | |- | ||
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | |[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | ||
Sumire Kitahara, MD | Sumire Kitahara, MD | ||
|6/6/24|| || | |6/6/24|| || | ||
| ||SK|| || | | ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Positive | |Anaplastic Large Cell Lymphoma, ALK-Positive | ||
| Line 2,766: | Line 2,759: | ||
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | |[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee); | ||
Sumire Kitahara, MD | Sumire Kitahara, MD | ||
|6/6/24|| || | |6/6/24|| || | ||
| ||SK|| || | | ||SK|| || | ||
|Anaplastic Large Cell Lymphoma, ALK-Negative | |Anaplastic Large Cell Lymphoma, ALK-Negative | ||
| Line 2,775: | Line 2,768: | ||
|- | |- | ||
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD | |[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD | ||
| | |9/22/2025 | ||
|1/1/2026 | |||
|Pending|| ||SK|| || | |||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma | |Breast Implant-Associated Anaplastic Large Cell Lymphoma | ||
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | ||
| Line 2,783: | Line 2,777: | ||
| | | | ||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | !Disease (5th Edition) | ||
| | | !Page Type | ||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |||
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | |||
|follow-up needed | |||
| || ||SK|| ||prior authors not available | |||
|Angioimmunoblastic T-cell Lymphoma | |Angioimmunoblastic T-cell Lymphoma | ||
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | |Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG | ||
| Line 2,792: | Line 2,803: | ||
|- | |- | ||
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | |[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023 | ||
| | | |follow-up needed | ||
| || ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,808: | Line 2,820: | ||
|- | |- | ||
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD | |[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD | ||
| | |10/14/2025 | ||
| | | |12/3/2025 | ||
|Pending | |||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,818: | Line 2,832: | ||
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | |[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee); | ||
Andrew Siref, MD | Andrew Siref, MD | ||
| | |10/14/2025|| ||Pending|| ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,825: | Line 2,839: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease|| | |[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD | ||
|1/6/2026 | |||
| | | 2/3/2026||Pending | ||
| ||Pending | |||
| ||SK|| || | | ||SK|| || | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,842: | Line 2,855: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || | |[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| || | ||
| Line 2,868: | Line 2,865: | ||
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD | |[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD | ||
|3/25/2024 | |3/25/2024 | ||
| || | | 11/17/2025||Pending | ||
| ||SK|| || | |||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,877: | Line 2,875: | ||
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD | |[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD | ||
|3/25/2024 | |3/25/2024 | ||
| || | | 11/17/2025||Pending | ||
| ||SK|| ||prior authors not available | |||
|Systemic EBV-Positive T-cell Lymphoma of Childhood | |Systemic EBV-Positive T-cell Lymphoma of Childhood | ||
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | |Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA | ||
| Line 2,883: | Line 2,882: | ||
|11/21/2021 | |11/21/2021 | ||
| | | | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | | | ||
| Line 2,978: | Line 2,993: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |- | ||
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]] | |[[HAEM5:Littoral cell angioma|Littoral cell angioma]] | ||
| Line 3,042: | Line 3,041: | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|NEW (No Prior) | |NEW (No Prior) | ||
|- | |||
!Disease (5th Edition) | |||
!Page Type | |||
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses) | |||
!Date Assigned to Author (5th Edition) | |||
!Target Completion Date (5th Edition) | |||
!Content Status (5th Edition)(Pending or Complete) | |||
!Date Completed by Author (5th Edition) | |||
!Associate Editor | |||
!Date of Last Editor Review (5th Edition) | |||
!Notes (5th Edition) | |||
!Correlated Prior Disease Name (4th Edition) | |||
!Correlated Prior Author (4th Edition) | |||
!Prior Content Status (4th Edition)(Pending or Complete) | |||
!Prior Date of Last Editor Review (4th Edition) | |||
!Prior Notes (4th Edition) | |||
|- | |- | ||
| | | | ||